



232-Pharmaceuticals Declaration

[Save](#)[Reset Form](#)

Complete this form if you have products flagged as pharmaceuticals subject to 232 duties per [91 FR 18183](#), [91 FR 60360](#), and [CSMS #69395344](#), [CSMS #70054007](#). If you need more space, please attach a list of goods to this form and indicate all elements of the table below. Failure to pay duties on subject goods can result in adverse action from CBP. By signing this form, you acknowledge that you have read the entire form and understand your responsibilities as the importer of record.

Part #/Product ID	Description	HTSUS	Country of Origin	99 Number to Declare

Complete for Single Shipment Declarations ONLY

Shipment Entry No., Invoice or Reference No.: _____

Deringer will no longer accept paper blanket forms starting on October 1, 2026. Blanket declarations will need to be submitted on our new [DocPort platform](#).

I hereby certify that the previous statements regarding my products are true and correct to the best of my knowledge.

Company Name: _____ Account #: _____

Name of Certifying Individual: _____ Title: _____

Phone No.: _____ Email: _____

Signature: _____ Date: _____

Further Guidance

Effective July 31, 2026 for some companies, Section 232 duties are due on certain patented pharmaceuticals per [91 FR 18183](#), [91 FR 60360](#) ([Annexes for easier searching](#), (c) are the subject HTSUS numbers). Further guidance can be found in [CSMS #69395344](#) and [CSMS #70054007](#). For companies not identified by the secretary of commerce, Section 232 duties on certain pharmaceutical articles are effective September 29, 2026. Imports of United States-origin pharmaceutical products are not subject to the tariffs imposed by the Proclamation. For purposes of these duties, the following definitions apply:

“Pharmaceutical articles” refers to imported articles classifiable in the provisions enumerated in this subdivision that are finished pharmaceutical products or that are active pharmaceutical ingredients (including key starting materials for active pharmaceutical ingredients) classifiable in the provisions enumerated in this subdivision used to make finished pharmaceutical products. Inactive ingredients and excipients are not pharmaceutical articles.”

“Patented pharmaceutical articles” are pharmaceutical articles that are subject to a valid, unexpired U.S. patent and are listed in the U.S. Food and Drug Administration’s (“FDA”) Approved Drug Products with Therapeutic Equivalence Evaluations (“Orange Book”) or in the FDA’s Lists of Licensed Biological Products (“Purple Book”); and ingredients (active pharmaceutical ingredients and key starting materials) for such articles.

"Generic pharmaceutical articles" are FDA-approved pharmaceutical articles, and associated ingredients, that are not subject to a valid, unexpired U.S. patent and are off exclusivity. A generic pharmaceutical article is an active pharmaceutical ingredient or any component in a finished dosage form product that is used in a drug product or biosimilar biological product approved pursuant to a qualifying application; or a drug product or biosimilar biological product approved or licensed pursuant to a qualifying application; or an unpatented animal health product. A qualifying application is: (a) an abbreviated new drug application submitted under section 505(j) of the Federal Food, Drug, and Cosmetic Act ("FDCA"); (b) a new drug application submitted under section 505(b)(2) of the FDCA that has been requested to be or that has been deemed therapeutically equivalent to a listed drug; (c) a biosimilar biologics application submitted under section 351(k) of the Public Health Services Act; or (d) an application for an authorized generic drug or authorized biological product, as those terms are described in section 505(t) of the FDCA and 42 U.S.C. § 1320f1(e)(2)(B)(ii), provided that the products are imported by a generic or biosimilar manufacturer.

Chapter 99 Numbers for Section 232 Pharmaceuticals:

9903.04.60 – Patented pharmaceutical articles classifiable in any HTSUS listed in U.S. Note 40(c) that are not imported for companies identified by the Secretary and imported on or after 9/29/26. Rate of duty is 100%

9903.04.61 – Patented pharmaceutical articles classifiable in any HTSUS listed in U.S. Note 40(c) imported for companies identified by the Secretary and imported on or before 9/28/26. Rate of 232 duty is 0%. **No longer in effect for goods entered after 12:01 a.m. on September 29, 2026.**

9903.04.62 – Patented pharmaceutical articles classifiable in any HTSUS listed in U.S. Note 40(c) that are the product of Japan, an EU country, South Korea, Switzerland, or Liechtenstein. Rate of duty is 15%.

9903.04.63 – Patented pharmaceutical articles classifiable in any HTSUS listed in U.S. Note 40(c) that are the product of the United Kingdom. Rate of 232 duty is 0% per [CSMS #69415934](#).

9903.04.64 - Patented pharmaceutical articles classifiable in any HTSUS listed in U.S. Note 40(c) imported for companies subject to an onshoring plan approved by the Secretary of Commerce. Rate of 232 duty is 20%. Effective for goods entered for consumption, or withdrawn from warehouse for consumption, on or after 12:01 a.m. eastern time on April 2, 2030, the duty rate for 9903.04.64 increases to 100%.

9903.04.65 - Patented pharmaceutical articles classifiable in any HTSUS listed in U.S. Note 40(c) that meet the requirements under 9903.04.64 AND are imported for companies that have entered into a Most-Favored-Nation pharmaceutical pricing agreement with the Commerce Department. Rate of 232 duty is 0%. Expires January 20, 2029.

9903.04.66 – Drugs and associated ingredients classifiable in any HTSUS listed in U.S. Note 40(c) for all approved indications that are designated as orphan pursuant to the Orphan Drug Act and its implementing regulations; nuclear medicines; plasma derived therapies; fertility treatments; cell and gene therapies; antibody drug conjugates; medical countermeasures related to chemical, biological, radiological and nuclear threats; or other specialty pharmaceutical products identified by the Secretary of Commerce or pharmaceutical products for animal health imported from a jurisdiction that has a current or forthcoming trade and security framework or that meet an urgent U.S. health need. The Secretary shall publish a Federal Register notice when the conditions above are met and shall notify CBP of all such products. Products of the following jurisdictions are eligible to use 9903.04.66: Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, European Union (Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden), Guatemala, India, Indonesia, Japan, Jordan, Malaysia, North Macedonia, Republic of Korea, Switzerland, Liechtenstein, Taiwan, Thailand, United Kingdom, and Vietnam. Rate of 232 duty is 0%.

9903.04.67 – Generic pharmaceutical articles as defined above. Rate of 232 duty is 0%.

9903.04.68 – Pharmaceutical products with an active pharmaceutical ingredient packaged in dosage form that is a product of the United States. Rate of 232 duty is 0%.

9903.04.69 – Articles that are classifiable under any HTSUS listed in U.S. Note 40(c) that are not "pharmaceutical articles" as defined above OR are "pharmaceutical articles" but are neither "patented pharmaceutical articles" nor "generic pharmaceutical articles" as defined above. Rate of 232 duty is 0%.

9903.04.70 - Pharmaceutical articles and associated ingredients provided for in U.S. Note 40(c) that are solely for use in clinical trials, research and development, or other non-commercial applications. Rate of 232 duty is 0%